Pravin  Dugel net worth and biography

Pravin Dugel Biography and Net Worth

Executive Chairman, President and CEO of Ocular Therapeutix

Pravin U. Dugel, MD has held previous leadership roles including President of IVERIC Bio, Inc., Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers and 35 book chapters and has been invited to give prestigious named lectures at marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, Nepal, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, the Czech Republic, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Honor Award, Senior Honor Award and Lifetime Achievement Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.

Additionally, he has been elected to the Retina Society, Macula Society, and the Retina Hall of Fame. Dr. Dugel has served as the Chair of the Scientific Advisory Board for major companies, including Novartis, Roche, Genentech, Allergan (Abbvie), Oxurion (Thrombogenics), Oculis, and Alcon. He has consulted for over 50 companies and has previously served on the IVERIC Bio and Aerpio Therapeutics Boards of Directors. Dr. Dugel has been a member of the Board of Directors and Chair of Orbis International’s Medical Advisory Board and Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery. In Arizona, Dr. Dugel founded an aviation company allowing him to travel to the Navajo, Hopi and Pima Indian Reservations to treat Native American patients suffering from preventable blindness. Dr. Dugel was born in Kathmandu, Nepal, grew up in Vienna, Austria and attended Harrow School in London, England. He graduated summa cum laude from Columbia University in New York City and was elected to the Phi Beta Kappa Society. He was also captain of the Columbia Squash team. He then attended the UCLA School of Medicine, completing his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and surgical retina fellowship at the USC Eye Institute, where he received both the Heed Foundation Fellowship award and Ronald G. Michels Foundation Fellowship award.

What is Pravin Dugel's net worth?

The estimated net worth of Pravin Dugel is at least $25.84 million as of February 24th, 2025. Dr. Dugel owns 3,520,318 shares of Ocular Therapeutix stock worth more than $25,839,134 as of April 2nd. This net worth approximation does not reflect any other investments that Dr. Dugel may own. Learn More about Pravin Dugel's net worth.

How old is Pravin Dugel?

Dr. Dugel is currently 60 years old. There are 3 older executives and no younger executives at Ocular Therapeutix. The oldest executive at Ocular Therapeutix is Dr. Peter K. Jarrett Ph.D., Chief Technology Officer, who is 67 years old. Learn More on Pravin Dugel's age.

How do I contact Pravin Dugel?

The corporate mailing address for Dr. Dugel and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at chris.brinzey@westwicke.com. Learn More on Pravin Dugel's contact information.

Has Pravin Dugel been buying or selling shares of Ocular Therapeutix?

Pravin Dugel has not been actively trading shares of Ocular Therapeutix in the last ninety days. Most recently, Pravin Dugel sold 21,475 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a transaction totalling $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. Learn More on Pravin Dugel's trading history.

Who are Ocular Therapeutix's active insiders?

Ocular Therapeutix's insider roster includes Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.

Are insiders buying or selling shares of Ocular Therapeutix?

During the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 45,949 shares worth more than $340,138.76. The most recent insider tranaction occured on February, 24th when insider Pravin Dugel sold 21,475 shares worth more than $147,533.25. Insiders at Ocular Therapeutix own 3.5% of the company. Learn More about insider trades at Ocular Therapeutix.

Information on this page was last updated on 2/24/2025.

Pravin Dugel Insider Trading History at Ocular Therapeutix

See Full Table

Pravin Dugel Buying and Selling Activity at Ocular Therapeutix

This chart shows Pravin Dugel's buying and selling at Ocular Therapeutix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Ocular Therapeutix Company Overview

Ocular Therapeutix logo
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $7.34
Low: $6.42
High: $7.34

50 Day Range

MA: $7.47
Low: $5.93
High: $8.51

2 Week Range

Now: $7.34
Low: $4.06
High: $11.78

Volume

1,867,225 shs

Average Volume

1,548,497 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49